Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIntron for HCC Prevention in HCV Cirrhosis
NCT00759109Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2002
- Primary completion
- Nov 2009
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b in hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started Mar 2002; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00759109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00759109.